---
title: "US approves new Parkinson’s drug developed by AbbVie"
description: "Most outlets reported the FDA’s approval of AbbVie’s Parkinson’s drug, tavapadon, and noted the company’s acquisition of Cerevel Therapeutics in 2023 to gain access to the drug. ARY News mentioned the $8.7 billion acquisition amount, while ProPakistani provided a more concise summary of the approval and acquisition without specifying the financial figure."
url: https://harzaviya.com/stories/11128-us-fda-approves-new-parkinson-s-drug
site: HarZaviya
language: en
---

# US approves new Parkinson’s drug developed by AbbVie

health · updated 28 Sep 2026, 3:54 PM PKT · 26–28 Sep 2026 · 2 articles from 2 outlets

**HarZaviya summary** — how 2 outlets covered this, generated automatically from their headlines and excerpts:

> Most outlets reported the FDA’s approval of AbbVie’s Parkinson’s drug, tavapadon, and noted the company’s acquisition of Cerevel Therapeutics in 2023 to gain access to the drug. ARY News mentioned the $8.7 billion acquisition amount, while ProPakistani provided a more concise summary of the approval and acquisition without specifying the financial figure.

## Same story from 2 outlets

Each outlet's own headline, most recent first — read any at its source.

- **ProPakistani** — [US FDA Approves New Parkinson’s Drug](https://propakistani.pk/2026/09/28/us-fda-approves-new-parkinsons-drug/) · 28 Sep 2026, 3:54 PM PKT
  > The US Food and Drug Administration has approved AbbVie’s treatment for Parkinson’s disease in adults. The drug, tavapadon, was acquired… Read More
- **ARY News (English)** — [Tavapadon: US approves AbbVie’s drug for Parkinson’s disease](https://arynews.tv/tavapadon-us-approves-abbvies-drug-for-parkinsons-disease) · 26 Sep 2026, 5:57 PM PKT · 88% identical wording to the newest filing
  > The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes ​as...

2 articles from 2 outlets, 26–28 Sep 2026. Headlines and links belong to their outlets — HarZaviya links out and never copies article text.

---

HarZaviya compares how Pakistani outlets cover the same story. It stores and shows each outlet's headline and a short excerpt, and links out — it never copies article text, and every headline belongs to the outlet that wrote it. It takes no stance on any outlet.

Pages: [Top stories](https://harzaviya.com/) · [Latest headlines](https://harzaviya.com/feed) · [Archive](https://harzaviya.com/archive) · [Why](https://harzaviya.com/why) · [Sources](https://harzaviya.com/sources) · [Methodology](https://harzaviya.com/methodology) · [About](https://harzaviya.com/about) · [About the bot](https://harzaviya.com/about-bot)
Trackers: [Gold prices](https://harzaviya.com/gold-prices) · [Fuel prices](https://harzaviya.com/fuel-prices) · [Stock exchange](https://harzaviya.com/stock-exchange)

Any page on this site is available as markdown: send `Accept: text/markdown`, or add `.md` to the path.